The LRRK2-in-1 compound was chosen to test in this system, as it is one of the few compounds that targets both the mutant and wild-type forms of LRRK2 [28] and hence, would be applicable for the treatment of both LRRK2 mutation-carrying and sporadic PD patients. The gene discussed is LRRK2; the disease is Parkinson disease.